Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 243,638,240
  • Shares Outstanding, K 3,100,512
  • Annual Sales, $ 45,811 M
  • Annual Income, $ 5,955 M
  • 60-Month Beta 0.47
  • Price/Sales 5.32
  • Price/Cash Flow 14.65
  • Price/Book 6.19
Trade AZN with:

Options Overview Details

View History
  • Implied Volatility 18.70% ( -1.71%)
  • Historical Volatility 18.50%
  • IV Percentile 6%
  • IV Rank 18.99%
  • IV High 31.19% on 10/16/23
  • IV Low 15.77% on 05/28/24
  • Put/Call Vol Ratio 0.19
  • Today's Volume 8,150
  • Volume Avg (30-Day) 8,944
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 135,365
  • Open Int (30-Day) 122,360

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 1.07
  • Number of Estimates 6
  • High Estimate 1.16
  • Low Estimate 0.98
  • Prior Year 0.87
  • Growth Rate Est. (year over year) +22.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
77.69 +1.88%
on 09/13/24
87.68 -9.72%
on 08/30/24
-5.63 (-6.64%)
since 08/19/24
3-Month
76.30 +3.74%
on 07/09/24
87.68 -9.72%
on 08/30/24
+0.73 (+0.93%)
since 06/18/24
52-Week
60.47 +30.89%
on 02/12/24
87.68 -9.72%
on 08/30/24
+12.48 (+18.72%)
since 09/19/23

Most Recent Stories

More News
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again

For over a decade, these two drugmakers consistently outperformed the benchmark index and could do it again.

ABBV : 194.02 (+0.56%)
AZN : 79.04 (+0.59%)
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung cancer...

AZN : 79.04 (+0.59%)
PFE : 29.73 (-0.07%)
MRK : 117.52 (-0.94%)
LLY : 912.95 (+0.88%)
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease

AstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab) for a new indication. The regulatory body has now approved Fasenra for treating adult patients with...

REGN : 1,156.80 (+1.58%)
SNY : 58.24 (+1.34%)
AZN : 79.04 (+0.59%)
GSK : 41.87 (-1.32%)
Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives

The urgent need for innovative technologies to accelerate the development of life-saving %Cancer therapies has never been more critical. With millions of lives and billions of dollars at stake, the potential...

MRK : 117.52 (-0.94%)
NVS : 116.41 (+0.38%)
KTRA : 0.1781 (+1.77%)
RKV.VN : 0.085 (unch)
RHHBY : 39.4800 (-0.33%)
XBIT : 7.88 (+5.07%)
BMRN : 71.43 (+0.41%)
AZN : 79.04 (+0.59%)
SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing

/CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a new...

AZN : 79.04 (+0.59%)
SOPH : 4.14 (-5.26%)
AstraZeneca’s Stock Falls 5% As Cancer Drug Trial Disappoints

Shares of AstraZeneca (AZN) are down 5% after the British pharmaceutical company reported disappointing ...

AZN : 79.04 (+0.59%)
GSK's Respiratory Drug Nucala Meets Goal in COPD Study

GSK’s GSK phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti-IL5 biologic, for treating chronic obstructive pulmonary disease (COPD), met its primary endpoint.Data from the...

REGN : 1,156.80 (+1.58%)
SNY : 58.24 (+1.34%)
AZN : 79.04 (+0.59%)
GSK : 41.87 (-1.32%)
3 Market-Beating Stocks to Buy for Less Than $100

These stocks are all up more than 20% this year.

SBUX : 96.85 (+0.76%)
AZN : 79.04 (+0.59%)
CHWY : 30.99 (+0.29%)
CMG : 57.60 (+1.18%)
As Radiotherapy Redefines Cancer Care, Here's the Stock to Buy Near 52-Week Highs

A new generation of radiotherapies are redefining cancer care, offering the potential for a more powerful treatment with fewer side effects. It could become a mainstream therapy for the big "traditional"...

LLY : 912.95 (+0.88%)
AZN : 79.04 (+0.59%)
BMY : 49.60 (-0.28%)
NVS : 116.41 (+0.38%)
PFE : 29.73 (-0.07%)
Here's What AstraZeneca's CEO Has to Say About the Weight Loss Drugs Market

The winners of today might not compete in the lucrative new segment of tomorrow.

LLY : 912.95 (+0.88%)
AZN : 79.04 (+0.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 80.06
2nd Resistance Point 79.66
1st Resistance Point 79.12
Last Price 79.04
1st Support Level 78.18
2nd Support Level 77.78
3rd Support Level 77.24

See More

52-Week High 87.68
Last Price 79.04
Fibonacci 61.8% 77.28
Fibonacci 50% 74.07
Fibonacci 38.2% 70.86
52-Week Low 60.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar